“Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma”. SKIN The Journal of Cutaneous Medicine 5, no. 1 (January 1, 2021): s2. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/1154.